The effect of 3-(5-nitro-2-thienyl)-9-chloro-5-morpholin-4-yl[1,2,4] triazolo[4,3-c]quinazoline on cell growth, cell cycle, induction of DNA fragmentation, and activity of caspase 3 in murine leukemia L1210 cells and fibroblast NIH-3T3 cells

Cell Biochemistry and Function

Volumn 24, Issue 6, 2006, Pages 519-530

  Jantova S ^a   Letasiova S ^a   Repicky A ^a   Ovadekova R ^a   Lakatos B ^a  

^a SLOVAK UNIVERSITY OF TECHNOLOGY   (Slovakia)

Author keywords

Apoptosis; Caspase 3; Cell cycle; Cell growth; L1210 and NIH 3T3 cells; Quinazoline derivative

Indexed keywords

3 (5 NITRO 2 THIENYL) 9 CHLORO 5 MORPHOLIN 4 YL[1,2,4]TRIAZOLO[4,3 C]QUINAZOLINE; CASPASE 3; DNA FRAGMENT; F ACTIN; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; IC 50; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FIBROBLASTS; MICE; MOLECULAR STRUCTURE; NIH 3T3 CELLS; QUINAZOLINES; TIME FACTORS; TRIAZOLES;

MURINAE;

EID: 33751172298     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1296     Document Type: Article

References (47)

1. Wiseloge FW. Survey of antimalarial drugs 1941-1945. In Advances in Heterocyclic Chemistry, Vol.1, Armarego WLF (ed.). Academic Press: New York, 1963; 304.
2. Abdel-Rahman TM. Synthesis of some new biologically active 2,3-disubstituted quinazolin-4-ones. Boll Chim Farm 1998; 137: 43-47.
3. Farghaly AM, Chaaban I, Khalil MA, Bekhit AA. Non-steroidal antiinflammatory agents. Synthesis of novel 2-pyrazolyl-4(3)-quinazolinones. Arch Pharmacol 1990; 323: 833-836.
4. Pomarnacka E, Angielski S, Hoppe A. Derivatives of 4-chloro-5-sulfanoyl- benzoic acid. 8. Synthesis and diuretic activity of pyrazole[3,2-b] quinazoline and 1-benzoylpyrazole derivatives. Acta Polon Pharm 1984; 41: 141-151.
5. Kornet MJ. Synthesis and anticonvulsant activity of 3-alkyl-3,4-dihydro- 2(1H)-quinazolinones. J Heterocyclic Chem 1992; 29: 103-105.
6. Shimoyama M, Ogino K, Tanaka Y, Ikeda T, Hisatome I. Hemodynamic basic for the acute cardiac effects of troglitazone in isolated perfused rat hearts. Diabetes 1999; 3: 609-615.
7. 2 phase and cell death induced by cisplatin. J Natl Cancer Inst 1990; 82: 749-754.
8. Naithani PK, Palit G, Srivastava VK, Shanker K. 2,3-Disubstituted quinazolinones and their antiparkinsonian activity. Ind J Chem Sect B, Org Chem Incl Med Chem 1989; 28: 745-750.
9. Loriga M, Vitale G, Paglietti G. Quinoxaline chemistry. Part 9. Quinoxaline analogues of trimetrexate (TMQ) and 10-propargyl-5,8-dideazafolic acid (CB3717) and its precursors. Synthesis and evaluation of in vitro anticancer activity. Farmaco 1998; 53: 139-149.
10. Sotelo-Mundo RR, Ciesla J, Dzík JM, et al. Crystal structures of rat thymidylate synthase inhibited by Tomudex, a potent anticancer drug. Biochemistry 1990; 38: 1087-1094.
11. Jantová S, Urbančíková M, Maliar T, et al. Biological activity of some 4-anilinoquinazolines: cytotoxic, genotoxic and antiprotease effects, induction of necrosis and changes of actin cytoskeleton. Neoplasma 2001; 1: 52-60.
12. Tonkinson JL, Marder P, Andis SL, et al. Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostatis. Cancer Chemother Pharmacol 1997; 39: 521-531.
13. Ranson M. Epidermal growth factor receptor tyrosine kinase inhibitors. Br J Cancer 2004; 90: 2250-2255.
14. Polshakov VI, Birdsall B, Frenkiel TA, Gargaro AR, Feeney J. Structure and dynamics in solution of the complex of Lactobacillus casei dihydrofolate reductase with the new lipophilic antifolate drug trimetrexate. Protein Sci 1999; 8: 467-481.
15. Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW, Baselga J. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res 1997; 3: 2099-2106.
16. Yamagishi M, Yamada Y, Ozaki K, et al. Biological activities and quantitative structure-activity relationships of spiro[imidazolidine-4-4′- (1H) quinazoline]-2,2,5(H)-triones as aldose reductase inhibitors. J Med Chem 1992; 35: 2085-2094.
17. Takemura Y, Jackman A. Folate-based thymidylate synthase inhibitors in cancer chemotherapy. Anti-Cancer Drugs 1997; 8: 3-16.
18. Hamel E, Lin CM, Plowman J, Wang H, Lee KH, Paull KD. Antitumour 2,3-dihydro-2-(aryl)-4(1H)-quinazolinone derivatives. Interactions with tubulin. Biochem Pharmacol 1996; 51: 53-59.
19. Modjtahedi H, Affleck K, Stubberfield C, Dean C. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. Int J Oncol 1998; 13: 335-342.
20. Holden SA, Teicher BA, Robinson MF, Northey D, Rosowsky A. Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo. Cancer Chemother 1995; 36: 165-171.
21. Kaye SB. New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer 1998; 78: 1-7.
22. Špirková K, Stankovský Š. Amidinoyl isothiocyanates in the synthesis of condensed quinazolines. Preparation of 3-aryl-5,9-disubstituted s-triazolo[4,3-c]quinazolines. Collect Czech Chem Commun 1991; 56: 1719-1724.
23. Špirková K, Stankovský Š, Horňáček J. Amidinoyl isothiocyanates in the synthesis of condensed quinazolines. Preparation of 3-aryl-5,9-disubstituted s-triazolo[4,3-c] quinazolines and their [1,5-c]isomers. Chem Paper 1993; 6: 382-385.
24. Jantová S, Ovádeková R, Letašiová S, Špirková K, Stankovský Š. Antimicrobial activity of some substituted triazoloquinazolines. Folia Microbiol 2005; 2: 90-94.
25. Letašiová S, Ovádeková R, Jantová S, Repický A, Stankovský Š. F-actin changes and DNA damage in murine melanoma cell line B16 induced by 3-(5-nitro-2-thienyl)-9-chloro-5- morpholin-4-yl[1,2,4]triazolo[4,3-c]quinazoline. In Abstract of XXIII. Xenobiochemic Symposium in Valtice, 16.-19.5. 2005; 74.
26. Lowry OH, Rosebrough NJ, Fair AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 143: 265.
27. 1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells. Biochem Pharm 2004; 68: 1453-1464.
28. Karnes Jr WE, Weller SG, Adjei PN, et al. Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cell. Gastroenterology 1998; 114: 930-939.
29. Narla RK, Liu XP, Myers DE, Uckun FM. 4-(3α-Bromo-4'hydroxylphenyl) -amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells. Clin Cancer Res 1998; 4: 1405-1414.
30. Faust RA, Tawfic S, Davis AT, Ahmed K. Apoptosis and growth inhibition of head and neck tumor cell line induced by epidermal growth factor receptor tyrosine kinase inhibitor. Oral Oncol 1999; 35: 290-295.
31. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053-2063.
32. Kimoto T, Hino K, Koya-Miyata S, et al. Cell differentiation and apoptosis of monocytic and promyeloytic leukemia cells (U-937 and HL-60) by tryptanthin, an active ingredient of Polygonum tinctorium Lour. Pathol Int 2001; 51: 315-325.
33. 1 arrest in oral squamous cell carcinoma cell lines. Oral Onco 2004; 1: 43-51.
34. Park JK, Lee SH, Kang JH, Nishio K, Saijo N, Kuh HJ. Synergistic interaction between gefitinib (Iressa, ZD1839) and oarlitaxel against human gastric carcinoma cells. Anticancer Drugs 2004; 8: 809-818.
35. Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Janne PA. Gefitinib induces apoptosis in the EGFR L858R nonsmall-cell lung cancer cell line H3255. Cancer Res 2004; 20: 7241-7244.
36. 1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells. Biochem Pharmacol 2004; 7: 1453-1464.
37. Sandstrom M, Johansson M, Andersson U, Bergh A, Bergenheim A, Henriksson R. The tyrosine kinase inhibitor ZD6474 inhibitors tumour growth in an intracerebral rat glioma model. Br J Cancer 2004; 6: 1174-1180.
38. Grunwald V, Hidalgo M. Development of the epidermal growth factor receptor inhibitor tarceva (OSI-774). Edv Exp Med Biol 2003; 532: 235-246.
39. Austin PF, Cook BL, Niederhoff RA, Manson SR, Coplen DE, Weintraub SJ. Inhibition of mitogenic signaling and induction of apoptosis in human bladder smooth muscle cells treated with doxazosin. J Urol 2004; 4: 1662-1665.
40. 2/M arrest and apoptosis in HL-60 by a potent anticancer agent, HMJ-38. Anticancer Res 2004; 3a: 1769-1778.
41. Fumarola C, Guidotii GG. Stress-induced apoptosi: toward a symmetry with receptor-mediated cell death. Apoptosis 2004; 9: 77-82.
42. Karnes WE, Weller SG, Adjei PN, et al. Inhibition of epidermal growth factor receptor kinase induces protease-dependent apotosis in human colon cancer cells. Gastroenterology 1998; 5: 930-939.
43. Kimoto T, Hino K, Koya-Miyata S, et al. Cell differentiation and apoptosis of monocytic and promyelocytic leukemia cells (U-937 and HL-60) by tryptanthrin, an active ingredient of Polygonum tinctorium Lour. Pathol Int 2001; 5: 315-325.
44. Janmaat ML, Kruyt FAE, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003; 9: 2316-2326.
45. Scott CW, Sobotka-Briner C, Wilkins DE, et al. Novel small molecule inhibitors of caspase 3 block cellular and biochemical features of apoptosis. J Pharmacol Exp Ther 2003; 1: 433-440.
46. 2/M arrest and apoptosis in HL-60 by a potent anticancer agent, HMJ-38. Anticancer Res 2004; 24: 1769-1778.
47. Chiang CF, Son EL, Wu GJ. Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasis. Prostate 2005; 4: 1778-1783.